Therapeutic response to a novel enzyme‑targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane

Aoyama,Nobutaka; Ogawa,Yasuhiro; Yasuoka,Miki; Iwasa,Hitomi; Miyatake,Kana; Yoshimatsu,Rika; Yamanishi,Tomoaki; Hamada,Norihiko; Tamura,Taiji; Kobayashi,Kana; Murata,Yoriko; Yamagami,Takuji; Miyamura,Mitsuhiko

doi:10.3892/ol.2016.5456

Therapeutic response to a novel enzyme‑targeting radiosensitization treatment (KORTUC II) for residual lesions in patients with stage IV primary breast cancer, following induction chemotherapy with epirubicin and cyclophosphamide or taxane

Authors:
- Nobutaka Aoyama
- Yasuhiro Ogawa
- Miki Yasuoka
- Hitomi Iwasa
- Kana Miyatake
- Rika Yoshimatsu
- Tomoaki Yamanishi
- Norihiko Hamada
- Taiji Tamura
- Kana Kobayashi
- Yoriko Murata
- Takuji Yamagami
- Mitsuhiko Miyamura
View Affiliations

Affiliations: Department of Diagnostic Radiology and Radiation Oncology, Kochi Medical School, Kochi University, Kochi 783‑8505, Japan, Hyogo Prefectural Kakogawa Medical Center, Kakogawa, Hyogo 675‑8555, Japan, Department of Pharmacy, Kochi Medical School, Kochi University, Kochi 783‑8505, Japan
Published online on: December 1, 2016 https://doi.org/10.3892/ol.2016.5456
Pages: 69-76
Copyright: © Aoyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Linac-based radiotherapy has a negligible effect on the majority of advanced neoplasms. Therefore, a novel radiosensitization treatment Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II (KORTUC II), which utilizes hydrogen peroxide and sodium hyaluronate was developed. The effectiveness of KORTUC II for the treatment of chemotherapy‑resistant supraclavicular lymph node metastases and recurrent breast cancers has previously been demonstrated. The present study evaluated the safety and efficacy of KORTUC II in patients with stage IV primary breast cancer. Seven patients (age range, 36‑65 years) were enrolled. All patients received induction chemotherapy prior to KORTUC II treatment and underwent positron emission tomography‑computed tomography (PET‑CT) examinations prior to and 2‑7 months following KORTUC II treatment, and every six months thereafter where possible. The radiotherapy regimen (x‑ray irradiation) was 2.75 gray (Gy)/fraction, 5 fractions/week for 16‑18 fractions with a total radiation dose of 44‑49.5 Gy. Administration of the KORTUC II agent (3‑6 ml: 3 ml for a lesion <3 cm in diameter and 6 ml for a lesion ≥3 cm) was initiated from the sixth radiotherapy fraction, and was conducted twice a week under ultrasonographic guidance. The therapeutic effects were evaluated by PET‑CT examinations prior to and following KORTUC II treatment. Of the seven lesions from the seven patients, five exhibited complete responses, two exhibited partial responses and none exhibited stable disease or progressive disease. The overall survival rate was determined to be 100% at 1 and 86% at 2 years post‑treatment. The mean duration of follow‑up by December 2014 was 51 months. The results of the PET‑CT studies indicated that KORTUC II treatment demonstrated marked therapeutic effects with satisfactory treatment outcomes and acceptable adverse effects.

View Figures

View References

1	Ogawa Y, Kubota K, Ue H, Nishioka A, Kariya S, Yokota N, Sasaki T, Suzuki K, Nakatani K, Yamanishi T, et al: Development and clinical application of a new radio sensitizer containing hydrogen peroxide and hyaluronic acid sodium for topical tumor injection - a new enzyme-targeting radiosensitization treatment, KORTUC II (Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II). Strahlenther Onkol. 183:100–101. 2007.
2	Ogawa Y, Ue H, Tsuzuki K, Tadokoro M, Miyatake K, Sasaki T, Yokota N, Hamada N, Kariya S, Hitomi J, et al: New radiosensitization treatment (KORTUC I) using hydrogen peroxide solution-soaked gauze bolus for unresectable and superficially exposed neoplasms. Oncol Rep. 19:1389–1394. 2008.PubMed/NCBI
3	Ogawa Y, Kubota K, Ue H, Kataoka Y, Tadokoro M, Miyatake K, Tsuzuki K, Yamanishi T, Itoh S, Hitomi J, et al: Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: A new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Int J Oncol. 34:609–618. 2009. View Article : Google Scholar : PubMed/NCBI
4	Miyatake K, Kubota K, Ogawa Y, Hamada N, Murata Y and Nishioka A: Non-surgical care for locally advanced breast cancer: Radiologically assessed therapeutic outcome of a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II) with systemic chemotherapy. Oncol Rep. 24:1161–1168. 2010. View Article : Google Scholar : PubMed/NCBI
5	Tokuhiro S, Ogawa Y, Tsuzuki K, Akima R, Ue H, Kariya S and Nishioka A: Development of a novel enzyme-targeting radiosensitizer (KORTUC) containing hydrogen peroxide for intratumoral injection for patients with low linear energy transfer-radioresistant neoplasms. Oncol Lett. 1:1025–1028. 2010.PubMed/NCBI
6	Hitomi J, Kubota K, Ogawa Y, Hamada N, Murata Y and Nishioka A: Non-surgical therapy and radiologic assessment of stage I breast cancer treatment with novel enzyme-targeting radiosensitization: Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II (KORTUC II). Exp Ther Med. 1:769–775. 2010. View Article : Google Scholar : PubMed/NCBI
7	Ogawa Y, Kubota K, Ue H, Tadokoro M, Matsui R, Yamanishi T, Hamada N, Kariya S, Nishioka A, Nakajima H, et al: Safety and effectiveness of a new enzyme-targeting radiosensitization treatment (KORTC II) for intratumoral injection for low-LET radioresistant tumors. Int J Oncol. 39:553–560. 2011.PubMed/NCBI
8	Tsuzuki A, Ogawa Y, Kubota K, Tokuhiro S, Akima R, Yaogawa S, Itoh K, Yamada Y, Sasaki T, Onogawa M, et al: Evaluation of changes in tumor shadows and Microcalcifications on mammography following KORTUC II, a new radiosensitization treatment without any surgical procedure for elderly patients with Stage I and II breast cancer. Cancers (Basel). 3:3496–3505. 2011. View Article : Google Scholar : PubMed/NCBI
9	Aoyama N, Ogawa Y, Kubota K, Ohgi K, Kataoka Y, Miyatake K, Tadokoro M, Yamanishi T, Ohnishi T, Hamada N, et al: Therapeutic response to a new enzyme-targeting radiosensitization treatment (KORTUC-SC) for patients with chemotherapy-resistant supraclavicular lymph node metastasis. J Cancer Res Ther. 1:215–219. 2013. View Article : Google Scholar
10	Aoyama N, Ogawa Y, Kubota K, Yasuoka M, Takahashi M, Iwasa H, Miyatake K, Yamanishi T, Hamada N, Tamura T, et al: Therapeutic response to a novel enzyme-targeting radiosensitization treatment (Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas) in patients with recurrent breast cancer. Oncol Lett. 12:29–34. 2016.PubMed/NCBI
11	Danforth DN Jr, Zujewski J, O'Shaughnessy J, Riseberg D, Steinberg SM, McAtee N, Noone M, Chow C, Chaudhry U, Lippman M, et al: Selection of local therapy after neoadjuvant chemotherapy in patients with Stage IIIA, B breast cancer. Ann Surg Oncol. 5:150–158. 1988. View Article : Google Scholar
12	Lorvidhaya V, Kamnerdsupaphon P, Chitapanarux I, Sukthomya V and Tonusin A: Cisplatin and gemcitabine in patients with metastatic cervical cancer. Gan To Kagaku Ryoho. 31:1057–1062. 2004.PubMed/NCBI
13	Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, et al: Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): A randomized, open-label, multicenter, phase 3 trial. Lancet Oncol. 16:436–446. 2015. View Article : Google Scholar : PubMed/NCBI
14	Karasawa K, Saito M, Hirowatari H, Izawa H, Furuya T, Ozawa S, Ito K, Suzuki T and Mitsuhashi N: The role of chemoradiotherapy in patients with unresectable T4 breast tumors. Breast Cancer. 20:254–261. 2013. View Article : Google Scholar : PubMed/NCBI
15	Johnson CJ, Graff R, Moran P, Cariou C and Bordeaux S: Breast cancer stage, surgery, and survival statistics for Idaho's national breast and cervical cancer early detection program population, 2004–2012. Prev Chronic Dis. 12:E362015. View Article : Google Scholar : PubMed/NCBI
16	Mukai H, Watanabe T, Mitsumori M, Tsuda H, Nakamura S, Masuda N, Yamamoto N, Shibata T, Sato A, Iwata H and Aogi K: Final results of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment of early breast cancer: Japan Clinical Oncology Group Study JCORG306. Oncology. 85:336–341. 2013. View Article : Google Scholar : PubMed/NCBI
17	Yin Y, Zhang P, Xu BH, Zhang BL, Li Q, Yuan P, Cai RG, Wang JY, Wang X and Xu XZ: Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer. J Huazhong Univ Sci Technolog Med Sci. 33:262–265. 2013. View Article : Google Scholar : PubMed/NCBI
18	Matuschek C, Bölke E, Roth S, Orth K, Lang I, Bojar H, Janni JW, Audretsch W, Nestle-Kraemling C, Lammering G, et al: Long-term outcome after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer and predictive factors for pathologic complete remission: Results of a multivariate analysis. Strahlenther Onkol. 188:777–781. 2012. View Article : Google Scholar : PubMed/NCBI
19	Genet D, Lejeune C, Bonnier P, Aubard Y, Venat-Bouvet L, Adjadj DJ, Martin J, Labourey JL, Benyoub A, Clavère P, et al: Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: Long-term follow-up. Br J Cancer. 97:883–887. 2007.PubMed/NCBI
20	Bollet MA, Sigal-Zafrani B, Gambotti L, Extra JM, Meunier M, Nos C, Dendale R, Campana F, Kirova YM, Diéras V, et al: Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: Result of phase II study. Eur J Cancer. 42:2286–2295. 2006. View Article : Google Scholar : PubMed/NCBI
21	Shaughnessy JN, Meena RA, Dunlap NE, Jain D, Riley EC, Quillo AR and Dragun AE: Efficacy of concurrent chemoradiotherapy for patients with locally recurrent or advanced inoperable breast cancer. Clin Breast Cancer. 15:135–142. 2015. View Article : Google Scholar : PubMed/NCBI